Hans Schambye, Galecto CEO
Galecto axes lead candidate in lung disease after PhIIb miss, stock craters
Galecto scrapped development of its lead candidate after the drug missed the primary endpoint in a mid-stage lung disease trial and said it is evaluating …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.